Skip to main content
. 2022 Jun 6;13:874211. doi: 10.3389/fneur.2022.874211

Figure 2.

Figure 2

Anti-PAD2 antibody levels in all patient groups. Anti-PAD2 Arbitrary Units (AU) for healthy controls (HC; n = 87) or people with multiple sclerosis (MS; n = 91), neuromyelitis optica (NMO; n = 32), and post-treatment Lyme disease syndrome (PTLD; n = 281) as measured by ELISA are shown. The dotted line represents the cutoff value for positivity at 4.5 AU. The median and 95% confidence interval of each group are shown. ****Mann–Whitney p-value < 0.0001 and ** < 0.01.